The promotion of endothelial cell attachment and spreading using FNIII10 fused to VEGF-A165

Biomaterials

Volumn 34, Issue 24, 2013, Pages 5958-5968

  Traub, Stephanie ^a   Morgner, Jessica ^b   Martino, Mikaël M ^c   Höning, Stefan ^a   Swartz, Melody A ^c   Wickström, Sara A ^b   Hubbell, Jeffrey A ^c   Eming, Sabine A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MAX PLANCK INSTITUTE FOR BIOLOGY OF AGEING   (Germany)

^c EPFL   (Switzerland)

Author keywords

Adhesion; Angiogenesis; Cell spreading; Fibronectin; Integrins; VEGF

Indexed keywords

ANGIOGENESIS; CELL SPREADING; FIBRONECTIN; INTEGRINS; VEGF;

ADHESION; BIOLOGICAL MATERIALS; BIOMATERIALS; BLOOD VESSELS; PROTEINS;

ENDOTHELIAL CELLS;

FIBRONECTIN; FNIII10 VEGF FUSION PROTEIN; HYBRID PROTEIN; RAC1 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ARTICLE; CELL ADHESION; CELL SPREADING; COVALENT BOND; EMBRYO; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN SECONDARY STRUCTURE; RECEPTOR BINDING; UMBILICAL VEIN ENDOTHELIAL CELL; WOUND HEALING;

ANIMALS; CELL ADHESION; CELL MOVEMENT; DIABETES MELLITUS, EXPERIMENTAL; ENZYME ACTIVATION; FIBRIN; FIBRONECTINS; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMOBILIZED PROTEINS; INTEGRIN ALPHAVBETA3; MALE; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RAC1 GTP-BINDING PROTEIN; RECOMBINANT FUSION PROTEINS; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

HARNESS;

EID: 84878114080     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.04.050     Document Type: Article

References (45)

1. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146:873-887.
2. Eming S.A., Hubbell J.A. Extracellular matrix in angiogenesis: dynamic structures with translational potential. Exp Dermatol 2011, 20:605-613.
3. Eming S.A., Brachvogel B., Odorisio T., Koch M. Regulation of angiogenesis: wound healing as a model. Prog Histochem Cytochem 2007, 42:115-170.
4. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006, 7:359-371.
5. Hanft J.R., Pollak R.A., Barbul A., van Gils C., Kwon P.S., Gray S.M., et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. JWound Care 2008, 17:30-32. 4-7.
6. Makinen K., Manninen H., Hedman M., Matsi P., Mussalo H., Alhava E., et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002, 6:127-133.
7. Olea F.D., Vera Janavel G., Cuniberti L., Yannarelli G., Cabeza Meckert P., Cors J., et al. Repeated, but not single, VEGF gene transfer affords protection against ischemic muscle lesions in rabbits with hindlimb ischemia. Gene Ther 2009, 16:716-723.
8. Rajagopalan S., Mohler E.R., Lederman R.J., Mendelsohn F.O., Saucedo J.F., Goldman C.K., et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003, 108:1933-1938.
9. Ozawa C.R., Banfi A., Glazer N.L., Thurston G., Springer M.L., Kraft P.E., et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. JClin Invest 2004, 113:516-527.
10. Ruhrberg C., Gerhardt H., Golding M., Watson R., Ioannidou S., Fujisawa H., et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002, 16:2684-2698.
11. Carmeliet P., Ng Y.S., Nuyens D., Theilmeier G., Brusselmans K., Cornelissen I., et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 1999, 5:495-502.
12. Legate K.R., Wickstrom S.A., Fassler R. Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev 2009, 23:397-418.
13. Wijelath E.S., Rahman S., Namekata M., Murray J., Nishimura T., Mostafavi-Pour Z., et al. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res 2006, 99:853-860.
14. Schense J.C., Hubbell J.A. Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa. Bioconjug Chem 1999, 10:75-81.
15. Ehrbar M., Djonov V.G., Schnell C., Tschanz S.A., Martiny-Baron G., Schenk U., et al. Cell-demanded liberation of VEGF(121) from fibrin implants induces local and controlled blood vessel growth. Circ Res 2004, 94:1124-1132.
16. Zisch A.H., Schenk U., Schense J.C., Sakiyama-Elbert S.E., Hubbell J.A. Covalently conjugated VEGF-fibrin matrices for endothelialization. JControl Release 2001, 72:101-113.
17. Byzova T.V., Goldman C.K., Pampori N., Thomas K.A., Bett A., Shattil S.J., et al. Amechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell 2000, 6:851-860.
18. Mahabeleshwar G.H., Chen J., Feng W., Somanath P.R., Razorenova O.V., Byzova T.V. Integrin affinity modulation in angiogenesis. Cell Cycle 2008, 7:335-347.
19. Reynolds L.E., Wyder L., Lively J.C., Taverna D., Robinson S.D., Huang X., et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002, 8:27-34.
20. Hodivala-Dilke K.M., McHugh K.P., Tsakiris D.A., Rayburn H., Crowley D., Ullman-Cullere M., et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. JClin Invest 1999, 103:229-238.
21. Hynes R.O. Areevaluation of integrins as regulators of angiogenesis. Nat Med 2002, 8:918-921.
22. Stupp R., Ruegg C. Integrin inhibitors reaching the clinic. JClin Oncol 2007, 25:1637-1638.
23. Weis S.M., Cheresh D.A. alphav integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med 2011, 1:a006478.
24. Carmeliet P. Integrin indecision. Nat Med 2002, 8:14-16.
25. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
26. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
27. Soldi R., Mitola S., Strasly M., Defilippi P., Tarone G., Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. Embo J 1999, 18:882-892.
28. Mahabeleshwar G.H., Feng W., Reddy K., Plow E.F., Byzova T.V. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res 2007, 101:570-580.
29. West X.Z., Meller N., Malinin N.L., Deshmukh L., Meller J., Mahabeleshwar G.H., et al. Integrin beta3 crosstalk with VEGFR accommodating tyrosine phosphorylation as a regulatory switch. PLoS One 2012, 7:e31071.
30. Hall H., Djonov V., Ehrbar M., Hoechli M., Hubbell J.A. Heterophilic interactions between cell adhesion molecule L1 and alphavbeta3-integrin induce HUVEC process extension invitro and angiogenesis invivo. Angiogenesis 2004, 7:213-223.
31. Hutchings H., Ortega N., Plouet J. Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. Faseb J 2003, 17:1520-1522.
32. Papo N., Silverman A.P., Lahti J.L., Cochran J.R. Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin. Proc Natl Acad Sci U S A 2011, 108:14067-14072.
33. Pytela R., Pierschbacher M.D., Ruoslahti E.A. 125/115-kDa cell surface receptor specific for vitronectin interacts with the arginine-glycine-aspartic acid adhesion sequence derived from fibronectin. Proc Natl Acad Sci U S A 1985, 82:5766-5770.
34. Lauer G., Sollberg S., Cole M., Krieg T., Eming S.A. Generation of a novel proteolysis resistant vascular endothelial growth factor(165) variant by a site-directed mutation at the plasmin sensitive cleavage site. Febs Lett 2002, 531:309-313.
35. Martino M.M., Tortelli F., Mochizuki M., Traub S., Ben-David D., Kuhn G.A., et al. Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci Transl Med 2011, 3:100ra89.
36. Hoffmann D.C., Textoris C., Oehme F., Klaassen T., Goppelt A., Romer A., et al. Pivotal role for alpha1-antichymotrypsin in skin repair. JBiol Chem 2011, 286:28889-28901.
37. Roth D., Piekarek M., Paulsson M., Christ H., Bloch W., Krieg T., et al. Plasmin modulates vascular endothelial growth factor-A-mediated angiogenesis during wound repair. Am J Pathol 2006, 168:670-684.
38. Gerhardt H., Golding M., Fruttiger M., Ruhrberg C., Lundkvist A., Abramsson A., et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. JCell Biol 2003, 161:1163-1177.
39. Pan Q., Chathery Y., Wu Y., Rathore N., Tong R.K., Peale F., et al. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. JBiol Chem 2007, 282:24049-24056.
40. Pierschbacher M.D., Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984, 309:30-33.
41. Frank S., Hubner G., Breier G., Longaker M.T., Greenhalgh D.G., Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. JBiol Chem 1995, 270:12607-12613.
42. Lerman O.Z., Galiano R.D., Armour M., Levine J.P., Gurtner G.C. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol 2003, 162:303-312.
43. Galiano R.D., Tepper O.M., Pelo C.R., Bhatt K.A., Callaghan M., Bastidas N., et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 2004, 164:1935-1947.
44. Kirchner L.M., Meerbaum S.O., Gruber B.S., Knoll A.K., Bulgrin J., Taylor R.A., et al. Effects of vascular endothelial growth factor on wound closure rates in the genetically diabetic mouse model. Wound Repair Regen 2003, 11:127-131.
45. Shen C.J., Raghavan S., Xu Z., Baranski J.D., Yu X., Wozniak M.A., et al. Decreased cell adhesion promotes angiogenesis in a Pyk2-dependent manner. Exp Cell Res 2011, 317:1860-1871.